Epstein-Barr_JJ
virus_NN
nuclear_JJ
antigen_NN
2_CD
transactivates_VBZ
latent_JJ
membrane_NN
protein_NN
LMP1_NN
._.

Several_JJ
lines_NNS
of_IN
evidence_NN
are_VBP
compatible_JJ
with_IN
the_DT
hypothesis_NN
that_IN
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
nuclear_JJ
antigen_NN
2_CD
-LRB-_-LRB-
EBNA-2_NN
-RRB-_-RRB-
or_CC
leader_NN
protein_NN
-LRB-_-LRB-
EBNA-LP_NN
-RRB-_-RRB-
affects_VBZ
expression_NN
of_IN
the_DT
EBV_NN
latent_JJ
infection_NN
membrane_NN
protein_NN
LMP1_NN
._.

We_PRP
now_RB
demonstrate_VBP
the_DT
following_NN
._.

-LRB-_-LRB-
i_LS
-RRB-_-RRB-
Acute_JJ
transfection_NN
and_CC
expression_NN
of_IN
EBNA-2_NN
under_IN
control_NN
of_IN
simian_JJ
virus_NN
40_CD
or_CC
Moloney_NN
murine_JJ
leukemia_NN
virus_NN
promoters_NNS
resulted_VBD
in_IN
increased_VBN
LMP1_NN
expression_NN
in_IN
P3HR-1-infected_JJ
Burkitt_NN
's_POS
lymphoma_NN
cells_NNS
and_CC
the_DT
P3HR-1_NN
or_CC
Daudi_NN
cell_NN
line_NN
._.

-LRB-_-LRB-
ii_LS
-RRB-_-RRB-
Transfection_NN
and_CC
expression_NN
of_IN
EBNA-LP_NN
alone_RB
had_VBD
no_DT
effect_NN
on_IN
LMP1_NN
expression_NN
and_CC
did_VBD
not_RB
act_VB
synergistically_RB
with_IN
EBNA-2_NN
to_TO
affect_VB
LMP1_NN
expression_NN
._.

-LRB-_-LRB-
iii_LS
-RRB-_-RRB-
LMP1_NN
expression_NN
in_IN
Daudi_NN
and_CC
P3HR-1-infected_JJ
cells_NNS
was_VBD
controlled_VBN
at_IN
the_DT
mRNA_NN
level_NN
,_,
and_CC
EBNA-2_NN
expression_NN
in_IN
Daudi_NN
cells_NNS
increased_VBD
LMP1_NN
mRNA_NN
._.

-LRB-_-LRB-
iv_LS
-RRB-_-RRB-
No_DT
other_JJ
EBV_NN
genes_NNS
were_VBD
required_VBN
for_IN
EBNA-2_NN
transactivation_NN
of_IN
LMP1_NN
since_IN
cotransfection_NN
of_IN
recombinant_JJ
EBNA-2_NN
expression_NN
vectors_NNS
and_CC
genomic_JJ
LMP1_NN
DNA_NN
fragments_NNS
enhanced_VBD
LMP1_NN
expression_NN
in_IN
the_DT
EBV-negative_JJ
B-lymphoma_NN
cell_NN
lines_NNS
BJAB_NN
,_,
Louckes_NN
,_,
and_CC
BL30_NN
._.

-LRB-_-LRB-
v_LS
-RRB-_-RRB-
An_DT
EBNA-2-responsive_JJ
element_NN
was_VBD
found_VBN
within_IN
the_DT
-512_CD
to_TO
+40_CD
LMP1_NN
DNA_NN
since_IN
this_DT
DNA_NN
linked_VBN
to_TO
a_DT
chloramphenicol_NN
acetyltransferase_NN
reporter_NN
gene_NN
was_VBD
transactivated_VBN
by_IN
cotransfection_NN
with_IN
an_DT
EBNA-2_NN
expression_NN
vector_NN
._.

-LRB-_-LRB-
vi_LS
-RRB-_-RRB-
The_DT
EBV_NN
type_NN
2_CD
EBNA-2_NN
transactivated_VBD
LMP1_NN
as_RB
well_RB
as_IN
the_DT
EBV_NN
type_NN
1_CD
EBNA-2_NN
._.

-LRB-_-LRB-
vii_LS
-RRB-_-RRB-
Two_CD
deletions_NNS
within_IN
the_DT
EBNA-2_NN
gene_NN
which_WDT
rendered_VBD
EBV_NN
transformation_NN
incompetent_JJ
did_VBD
not_RB
transactivate_VB
LMP1_NN
,_,
whereas_IN
a_DT
transformation-competent_JJ
EBNA-2_NN
deletion_NN
mutant_NN
did_VBD
transactivate_VB
LMP1_NN
._.

LMP1_NN
is_VBZ
a_DT
potent_JJ
effector_NN
of_IN
B-lymphocyte_NN
activation_NN
and_CC
can_MD
act_VB
synergistically_RB
with_IN
EBNA-2_NN
to_TO
induce_VB
cellular_JJ
CD23_NN
gene_NN
expression_NN
._.

Thus_RB
,_,
EBNA-2_NN
transactivation_NN
of_IN
LMP1_NN
amplifies_VBZ
the_DT
biological_JJ
impact_NN
of_IN
EBNA-2_NN
and_CC
underscores_VBZ
its_PRP$
central_JJ
role_NN
in_IN
EBV-induced_JJ
growth_NN
transformation_NN
._.

